Skip to main content

Low-Cost, Group-Based Lifestyle Intervention Aids Diabetes Outcomes

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 15, 2024.

By Lori Solomon HealthDay Reporter

THURSDAY, Aug. 15, 2024 -- Even individuals with a high genetic risk for type 2 diabetes (T2D) benefit from a low-cost, group-based intervention focused on healthy diet and physical activity, according to a study recently published online in the Journal of Clinical Endocrinology & Metabolism.

Maria Anneli Lankinen, Ph.D., from the University of Eastern Finland in Kuopio, and colleagues investigated whether a low or high genetic risk has effects on incident T2D in a group-based lifestyle intervention study. The analysis included men (aged 50 to 75 years) participating in the Metabolic Syndrome in Men cohort, with 315 characterized as having low genetic risk and 313 as having high genetic risk for T2D, as well as controls (196 low and 149 high genetic risk).

The researchers found that the three-year intervention significantly lowered the risk for T2D among the participants with a high genetic risk for T2D (hazard ratio, 0.30; 95 percent confidence interval, 0.16 to 0.56; P < 0.001). However, in the low genetic risk group, the effect was not significant (hazard ratio, 0.69; 95 percent confidence interval, 0.36 to 1.32; P = 0.262). Between the high and low genetic risk groups, the intervention effect was not significantly different. In both the low and high genetic risk groups, the intervention significantly ameliorated the worsening of glycemia and decreased weight.

"All individuals at risk of T2D should be encouraged to make lifestyle changes regardless of genetic risk," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted August 2024

Read this next

Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials

THURSDAY, June 12, 2025 -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower...

Adherence to Healthy Diet Improves Cardiometabolic Risk, Even Without Weight Loss

WEDNESDAY, June 11, 2025 -- A healthy diet improves cardiometabolic risk factors, even if not associated with weight loss (WL), according to a study published online June 5...

Mediterranean Diet Provides Some Relief for Nonconstipated Irritable Bowel Syndrome

TUESDAY, June 10, 2025 -- Adherence to a Mediterranean diet (MD) provides symptom relief in adults with diarrhea-predominant irritable bowel syndrome (IBS-D) or mixed bowel...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.